



# Apoptosis of Peripheral T Cells in Rodent Cardiac Allograft Recipients Induced by Donor-Specific Transfusion With Impaired Inducible Costimulator/B7 Homologous Protein Allorecognition

J.-F. Du, X.-F. Shen, X.-Q. Ji, G. Chen, X. Bai, F.-Y. Zuo, and B. Yu

## ABSTRACT

**Objective.** To investigate apoptosis of the CD8<sup>+</sup> T cells (T<sub>c</sub>) subpopulation in rodent cardiac allograft recipients, which were treated by donor specific transfusion combined with blockade of Inducible costimulator (ICOS)/B7 homologous protein (B7h) costimulation.

**Methods.** Donor hearts were heterotopically transplanted into the necks of recipient mice using Chen's technique. Postoperative graft survival was recorded. Both the percentage of CD3<sup>+</sup>CD8<sup>+</sup>ICOS<sup>+</sup> T<sub>c</sub> in recipients' peripheral blood and the apoptosis of CD8<sup>+</sup> T<sub>c</sub> in recipient draining lymph nodes were detected by flow cytometry analysis.

**Results.** In comparison with the allogeneic group, the survival of cardiac grafts was prolonged by combined treatment with  $5 \times 10^6$  ICOS-Fc-targeted B cells on day 0 of transplantation and 10 mg/kg/d ICOS-Fc on days 0 to 6 ( $84.38 \pm 29.14$  days versus  $7.00 \pm 0.76$  days,  $P < .01$ ). The treatment group showed a stable CD8<sup>+</sup>T<sub>c</sub> clone size in recipient peripheral blood ( $49.4\% \pm 3.11\%$  versus  $50.0\% \pm 2.46\%$ ,  $P > .05$ ); however, the percentage of CD3<sup>+</sup>CD8<sup>+</sup>ICOS<sup>+</sup> T<sub>c</sub> decreased significantly compared with the allogeneic group ( $7.5\% \pm 2.02\%$  versus  $14.0\% \pm 3.03\%$ ,  $P < .05$ ). Compared with allogeneic group, apoptosis of the CD8<sup>+</sup> T<sub>c</sub> subpopulation in recipient draining lymph nodes was up-regulated significantly at postoperative 7 days in the treatment group ( $19.53\% \pm 5.10\%$  versus  $8.70 \pm 3.14\%$ ,  $P < .05$ ).

**Conclusion.** Apoptosis of CD8<sup>+</sup> T<sub>c</sub> in recipient draining lymph nodes was enhanced by pretreatment with donor specific transfusion and impaired ICOS/B7h allorecognition, which may have been associated with the variation in the CD3<sup>+</sup>CD8<sup>+</sup>ICOS<sup>+</sup> T<sub>c</sub> subpopulation in peripheral blood and at least partially contributed to unresponsiveness toward cardiac allograft.

**I**MMUNOLOGIC BARRIERS remain the major challenge in solid organ transplantation. Accumulated data from rodent models have indicated that long-term survival of allografts relied on both the induction and maintenance of unresponsiveness, which involves several mechanisms

including apoptosis of alloreactive (allo-) T cells (T<sub>c</sub>). Previous results have revealed transfer of cardiac allograft unresponsiveness after donor-specific transfusion (DST) combined with blockade of inducible costimulator (ICOS)/B7 homologous protein (B7h) allorecognition.<sup>1</sup> Using this

From the Department of General Surgery (J.-F.D., X.-Q.J., G.C., X.B., F.-Y.Z., B.Y.), General Hospital of Beijing Military Command, Beijing, PR China; and Department of General Surgery (X.-F.S.), Affiliated Drum Tower Hospital, Nanjing Medical University, Nanjing, Jiangsu, PR China.

Jun-Feng Du and Xiao-Fei Shen contributed equally to this work.

This study was supported by National Nature Science Foundation of China (No. 81000189 and 81101860).

Address reprint requests to Bo Yu, MD, PhD, Department of General Surgery, General Hospital of Beijing Military Command, Beijing, PR China 100700. E-mail: [yubo6666@gmail.com](mailto:yubo6666@gmail.com)

0041-1345/13/\$—see front matter  
<http://dx.doi.org/10.1016/j.transproceed.2012.06.084>

© 2013 by Elsevier Inc. All rights reserved.  
360 Park Avenue South, New York, NY 10010-1710

model, we sought to investigate apoptosis among the CD8<sup>+</sup> T<sub>c</sub> subpopulation in the early period after heterotopic cardiac transplantation across full major histocompatibility complex mismatched strains using pretreatment with DST plus impaired ICOS/B7h allorecognition.

## MATERIALS AND METHODS

Male mice of inbred strains BALB/c (H-2<sup>d</sup>) and C57BL/6 (H-2<sup>b</sup>) and aged 6 to 8 weeks were obtained from our Experimental Animal Center and maintained in pathogen-free conditions. Our Guidelines for the Care and Use of Laboratory Animals were followed in this study.

The recombinant murine ICOS-Fc, of which the extracellular domain of murine ICOS was fused to the Fc region of human immunoglobulin G1 via a polypeptide linker has been described previously (R&D Systems, Inc, USA).<sup>2</sup> EZ-Sep Mouse 1X was purchased from Dakewe Biotech (China). RPMI 1640, fetal bovine serum (FBS), phosphate-buffered saline (PBS), propidium iodide (PI), ammonium-chloride-potassium (ACK) Lysis Buffer and binding buffer were all purchased from Invitrogen (USA). PE-Cy5-CD3 $\epsilon$  mAb, PE-CD8 $\alpha$  mAb, CD16/CD32 mAb, Percp-CD3 $\epsilon$  mAb, APC-CD8 mAb and Annexin V-FITC and PI Apoptosis Detection Kit were all purchased from BD Pharmingen (USA). FITC-ICOS mAb was purchased from eBioscience (Ireland, United Kingdom); B Cell Isolation Kit, from Miltenyi Biotec Inc (USA).

Resting splenocytes were harvested from mice by gradient centrifugation at 800g for 30 minutes using EZ-Sep Mouse 1 $\times$  to remove red blood cells. Following washing twice in ice-cold RPMI1640 supplemented with 5% FBS, untouched splenic B cells were isolated by magnetic separation using the B Cell Isolation Kit, according to the manufacturers' protocols. ICOS-Fc-targeted donor B cells were prepared as follows<sup>1,3</sup>; splenic B cells harvested from BALB/c mice were incubated with ICOS-Fc at a concentration of 100  $\mu$ g/mL at 4°C for 30 minutes in RPMI 1640 prior to extensive washing; finally, the cells were resuspended in PBS.

Donor hearts were heterotopically transplanted into the necks of recipient mice using Chen's technique.<sup>4</sup> Graft function was assessed daily by palpation; rejection was defined as the absence of detectable beat. Allografts that failed or graft recipients that died within 48 hours of surgery were considered to be technical failures and excluded from the analysis. Long-term allograft survival referred to survival time beyond 100 days; a median survival time > 100 days was recognized as allograft acceptance.

Recipient mice were assigned to five groups: the isogenic group including BALB/c donors and recipients did not undergo any treatment. In the allogeneic group, donor hearts from BALB/c mice were transplanted into C57BL/6 mice without treatment. A combination of 5  $\times$  10<sup>6</sup> ICOS-Fc-targeted B cells on day 0 and 10 mg/kg/d ICOS-Fc on days 0 to 6<sup>1</sup> were given to a treatment of donor BALB/c mice grafts into recipient C57BL/6 mice. Similarly, ICOS-Fc was administered at a dose of 10 mg/kg/d for 7 days to the ICOS-Fc group. The DST group received 5  $\times$  10<sup>6</sup> isolated donor B cells on the day of transplantation. Each injection was given in a total volume of 200  $\mu$ L PBS via the tail vein of the recipient.

Analysis of the T<sub>c</sub> subpopulation in peripheral blood was performed 7 days postoperatively. Briefly, peripheral blood collected from recipient mice and treated with 50 U/mL heparin sodium, underwent red blood cell (RBC) lysis using ACK buffer. RBC-depleted splenocytes were washed in PBS containing 5% FBS. Unlabeled anti-CD16/CD32 was used to block FcR binding; 1  $\times$  10<sup>6</sup> cells were stained with PE-Cy5-CD3 $\epsilon$  mAb, PE-CD8 $\alpha$  mAb, or FITC-ICOS mAb for flow cytometry analysis on a EPICS XL

(Beckman-Coulter), to detect the percentage of CD3<sup>+</sup>CD8<sup>+</sup> ICOS<sup>+</sup> T<sub>c</sub>.

The draining bilateral axillary and lateral axillary lymph nodes harvested at 7 days after heart transplantation yielded single-cell suspensions that were washed in PBS containing 5% FBS. Unlabeled anti-CD16/CD32 was used to block FcR binding. Then 1  $\times$  10<sup>6</sup> cells stained with Percp-CD3 $\epsilon$ mAb and APC-CD8 mAb were resuspended in apoptosis binding buffer according to the manufacturer's instructions. After incubation with Annexin V-FITC for 15 minutes the cells were stained with PI prior to detection. Using a gate on CD3<sup>+</sup>CD8<sup>+</sup> lymphocytes, the percentage of Annexin V<sup>+</sup>PI<sup>-</sup> cells was determined by four-color flow cytometry with analysis employing CellQuest acquisition software.

Survival data were analyzed using the Kaplan-Meier method with the log-rank test to evaluate the significance of survival differences between groups. Student *t* test was used to compare percentages of CD8<sup>+</sup> T<sub>c</sub> subpopulation apoptosis with *P* < .05 considered to be significant statistically.

## RESULTS

### Survival of Grafts

Table 1 shows all of the isogenic cardiac grafts to have survived more than 100 days. However, allografts were rejected within 8 days postoperatively among the allogeneic group (7.00  $\pm$  0.76 days, *n* = 8). In comparison, allograft survival was prolonged by either ICOS-Fc (13.13  $\pm$  1.55 days, *n* = 8, *P* < .05) or 5  $\times$  10<sup>6</sup> isolated donor B cells (21.50  $\pm$  2.56 days, *n* = 8, *P* < .05). Furthermore, graft survival in combined DST and ICOS/B7h blockade treatment group was significantly prolonged compared with the allogeneic group: 84.38  $\pm$  29.14 days (*n* = 8; *P* < .01).

### Variation of CD8<sup>+</sup> T<sub>c</sub> Subpopulation in Peripheral Blood of Recipient Mice

As shown in Fig 1, the percentage of total CD8<sup>+</sup> T<sub>c</sub> in the peripheral blood of allogeneic recipients increased markedly on day 7 after surgery, compared with that in the isogenic group (50.0%  $\pm$  2.46% versus 31.7%  $\pm$  2.33%, *P* < .05). Similar results were observed in the treatment group (49.4%  $\pm$  3.11% versus 50.0%  $\pm$  2.46%, *P* > .05). Consistent with that observation, the percentage of CD3<sup>+</sup>CD8<sup>+</sup>ICOS<sup>+</sup> T<sub>c</sub> subpopulation in the allogeneic group were much higher than that in the isogenic group (14.0%  $\pm$  3.03% versus 1.6  $\pm$  0.76%, *P* < .005); however, the combined treatment group showed a significantly decreased percentage of CD3<sup>+</sup>CD8<sup>+</sup>ICOS<sup>+</sup> T<sub>c</sub> compared

**Table 1. Prolonged Allograft Survival Achieved by the Combined Treatment of DST and ICOS/B7h Blockade**

Group	<i>n</i>	Graft Survival (d)	<i>P</i> Value (compared with allogeneic group)
Isogenic group	8	>100	
Allogeneic group	8	7.00 $\pm$ 0.76	
DST group	8	13.13 $\pm$ 1.55	<.05
ICOS-Fc group	8	21.50 $\pm$ 2.56	<.05
Treatment group	8	84.38 $\pm$ 29.14	<.01

DST, donor-specific transfusion; ICOS, inducible costimulator; B7h, B7 homologous protein.

Download English Version:

<https://daneshyari.com/en/article/4256141>

Download Persian Version:

<https://daneshyari.com/article/4256141>

[Daneshyari.com](https://daneshyari.com)